Company profile: NovaTarg
1.1 - Company Overview
Company description
- Provider of tissue-targeted medicine discovery and cancer treatment programs. NovaTarg Therapeutics is a privately owned pharmaceutical company with a leadership team experienced in drug discovery and a novel approach to the discovery of tissue-targeted medicines; offerings include NT1195, a treatment program aimed at addressing cancer.
Products and services
- Drug Discovery Leadership: Leadership team architects programs, leveraging drug-discovery experience to establish and guide pharmaceutical discovery initiatives within the privately owned company
- NT1195: NovaTarg develops a cancer-focused treatment program aimed at addressing cancer through therapeutic development conducted by NovaTarg Therapeutics
- Tissue-Targeted Medicines Discovery Approach: NovaTarg develops a novel tissue-targeted discovery approach for medicines, architected to enable the discovery of tissue-targeted medicines across therapeutic research
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovaTarg
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
Cequent Pharmaceuticals
HQ: United States
Website
- Description: Provider of TransKingdom RNA interference (tkRNAi) therapeutics using non-pathogenic bacteria to deliver RNAi into cells to silence disease-causing genes, with pre-clinical drug candidates for colon cancer prevention and inflammatory bowel disease, targeting a wide range of human diseases from inflammatory conditions to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cequent Pharmaceuticals company profile →
Oxford Pharmascience
HQ: United Kingdom
Website
- Description: Provider of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take, licensing its technologies and dossiers to a network of partners rather than manufacturing or selling directly to consumers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Pharmascience company profile →
InnoPharma
HQ: United States
Website
- Description: Provider of niche-generic, specialty pharmaceutical and bio-pharmaceutical product development, operating as a privately held pharmaceutical R&D company founded in 2005 and based in Piscataway, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InnoPharma company profile →
Regeneron
HQ: United States
Website
- Description: Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regeneron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovaTarg
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovaTarg
2.2 - Growth funds investing in similar companies to NovaTarg
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovaTarg
4.2 - Public trading comparable groups for NovaTarg
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →